Want to see LMRI full AI Analyst Report?
LMRI Stock Chart & Stats
$10.41
$0.16(1.56%)
At close: 4:00 PM EDT
$10.41
$0.16(1.56%)
Day’s Range― - ―
52-Week Range$6.45 - $19.45
Previous Close$10.36
Volume340.06K
Average Volume (3M)596.29K
Market Cap
$1.00B
Enterprise Value$1.74K
Total Cash (Recent Filing)$51.23M
Total Debt (Recent Filing)$967.45M
Price to Earnings (P/E)―
Beta0.98
Next Earnings
Aug 12, 2026EPS Estimate
0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.36
Shares Outstanding96,080,734
10 Day Avg. Volume398,784
30 Day Avg. Volume596,288
Financial Highlights & Ratios
PEG Ratio0.82
Price to Book (P/B)2.24
Price to Sales (P/S)1.28
P/FCF Ratio-205.07
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$15.75Price Target Upside51.30% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)0.76
Revenue Forecast (FY)$1.07B
Bulls Say, Bears Say
Bulls Say
Advanced Modality GrowthSustained double-digit PET growth and broader advanced modality expansion indicate structurally higher-margin volume mix. That durable demand supports revenue per scan, strengthens facility economics for de novo/JV rollouts, and underpins long-term margin and EBITDA sustainability.
Improving LeverageA materially lower debt-to-equity ratio reduces interest burden and financial risk, increasing flexibility to fund targeted growth, capex and integration costs. An improving leverage trajectory materially de-risks the capital structure over the medium term if profitability stabilizes.
Adjusted EBITDA ResilienceStable, high-teens to low-20s adjusted EBITDA margins despite seasonality and public-company costs show durable operating economics. This operating profitability provides a foundation for generating cash, funding rollouts, and absorbing integration costs while management executes de novo and JV expansion.
Bears Say
Weak Cash GenerationNegative quarterly free cash flow and a 2025 FCF turn negative highlight earnings-to-cash conversion volatility. Persistent FCF weakness limits self-funded expansion, raises refinancing reliance, and increases sensitivity to working-capital swings and seasonal headwinds over the coming 2–6 months.
Historical Negative Net MarginsAlthough recent quarters showed improvement, multi-year negative net margins reflect structural cost or mix issues that can erode shareholder returns. Until sustained bottom-line profitability is achieved, equity dilution, constrained ROE and limited capital return options remain durable risks.
Restrictive Debt CovenantsNew secured facilities with tighter covenant triggers and broad guarantees constrain capital flexibility. These covenants can limit additional debt, dividends, or transactions and increase default risk if revolver usage or leverage rises, restricting strategic options during growth or stress periods.
Lumexa Imaging Holdings, Inc. News
LMRI FAQ
What was Lumexa Imaging Holdings, Inc.’s price range in the past 12 months?
Lumexa Imaging Holdings, Inc. lowest stock price was $6.45 and its highest was $19.45 in the past 12 months.
What is Lumexa Imaging Holdings, Inc.’s market cap?
Lumexa Imaging Holdings, Inc.’s market cap is $1.00B.
When is Lumexa Imaging Holdings, Inc.’s upcoming earnings report date?
Lumexa Imaging Holdings, Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 10 days.
How were Lumexa Imaging Holdings, Inc.’s earnings last quarter?
Lumexa Imaging Holdings, Inc. released its earnings results on May 12, 2026. The company reported $0.187 earnings per share for the quarter, beating the consensus estimate of $0.123 by $0.064.
Is Lumexa Imaging Holdings, Inc. overvalued?
According to Wall Street analysts Lumexa Imaging Holdings, Inc.’s price is currently Undervalued.
Does Lumexa Imaging Holdings, Inc. pay dividends?
Lumexa Imaging Holdings, Inc. does not currently pay dividends.
What is Lumexa Imaging Holdings, Inc.’s EPS estimate?
Lumexa Imaging Holdings, Inc.’s EPS estimate is 0.15.
How many shares outstanding does Lumexa Imaging Holdings, Inc. have?
Lumexa Imaging Holdings, Inc. has 96,080,734 shares outstanding.
What happened to Lumexa Imaging Holdings, Inc.’s price movement after its last earnings report?
Lumexa Imaging Holdings, Inc. reported an EPS of $0.187 in its last earnings report, beating expectations of $0.123. Following the earnings report the stock price went down -23.333%.
Which hedge fund is a major shareholder of Lumexa Imaging Holdings, Inc.?
Currently, no hedge funds are holding shares in LMRI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lumexa Imaging Holdings, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.75 (51.30% Upside)
$15.75 (51.30% Upside)
Blogger Sentiment
Bullish
LMRI Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 391.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $476.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 8.5%
Last 30 Days ▼ 8.5%
Company Description
Lumexa Imaging Holdings, Inc.
Lumexa Imaging Holdings, Inc. manages and operates diagnostic imaging centers throughout the United States. These facilities deliver a comprehensive range of outpatient medical imaging solutions, encompassing advanced procedures like Magnetic Resonance Imaging (MRI), Computed Tomography (CT), and Positron Emission Tomography (PET) scans, in addition to standard diagnostic and screening services such as X-rays, ultrasounds, and mammography. The company was founded in 2018 and its primary base of operations is in Raleigh, North Carolina.
LMRI Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a constructive growth story: revenue and advanced modality volumes expanded (notably PET +23%), adjusted EBITDA held steady at $51.2 million, profitability returned to positive net income, and management reiterated full-year guidance while outlining disciplined growth via de novos, JVs and technology adoption. Near-term headwinds included a roughly $4 million weather and seasonality EBITDA drag, slower routine scans and mammography, higher public company and stock-based compensation costs, and a Q1 free cash flow shortfall. On balance, the operational momentum in high-margin advanced services, improved cash flow trajectory, successful JV and de novo activity, and affirmed guidance outweigh the transitory and timing-related challenges discussed on the call.View all LMRI earnings summariesLMRI Stock 12 Month Forecast
Average Price Target
$15.75
▲(51.30% Upside)
Ownership Overview
0.64% Insiders
12.41% Mutual Funds
10.21% Other Institutional Investors
74.36% Public Companies and
Individual Investors